The Einsteinium Foundation is the first non-profit dedicated to scientific research to be registered in the digital currency space. This month the Foundation pledged $1500 USD to diabetes research.
Canada / ACCESSWIRE / April 30th, 2014 / Devoted to fast-track the future with the modern means of digital currency, the Einsteinium Foundation continues to fund vital scientific research worldwide with the digital coin EMC2. Only two months in and they have made their second monthly donation: $1500 USD to diabetes research. The organization behind the EMC2 digital currency, the Einsteinium Foundation, has also legally registered in Canada as the first non-profit in the digital currency space dedicated to scientific research worldwide. EMC2, similar to Bitcoin, Litecoin and Doegecoin, is an increasingly popular scrypt based digital currency that implements proof-of-work algorithm.
the Einsteinium Foundation became an official Non-Profit Organization on April 7th, registered in Montreal with NPO corporation number: 882658-4: https://www.ic.gc.ca/app/scr/cc/CorporationsCanada/fdrlCrpSrch.html?locale=en_CA. Through being the first non-profit dedicated to scientific research to be registered in the world of digital currency, the Einsteinium Foundation hopes to secure grants and build long lasting relationships with other NPOs worldwide – in order to support future ground breaking science projects of all kinds.
April’s financial contribution of just over 500K EMC2, or $1500 USD, represents a 50% increase from last month’s donations; in line with the increasing popularity of the foundation’s digital currency EMC2.
The funds were pledged to NPO Mend Therapeutics for their vital research in inexpensive diabetes medicine. The research can potentially aid millions of people suffering from diabetes and related complication globally. According to the World Health Organization diabetes is predicted to become the seventh leading cause of death in the world by the year 2030. Diabetes is a leading cause of blindness, amputation, kidney failure and cardiovascular disease. 80% of diabetes deaths occur in low to middle income countries – hence affordable and accessible medication is crucial for survival.
“Mend Therapeutics is creating affordable drugs for the World’s 371 Mill diabetics who don’t have health insurance. Diabetic complications are catastrophic and include non-healing wounds leading to amputation. We want to develop a protein for diabetic wounds that can be manufactured at low cost, an important step in creating an affordable drug. If all patients, irrespective of economic status, can afford medications, they have a brighter future.” -Mend Therapeutics.